Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial

Thomas B. Powles, Tibor Csőszi, Mustafa Özgüroğlu et al. · The Lancet Oncology · 2021

Cited by 642 works. doi:10.1016/s1470-2045(21)00152-2

Authors

References